Mistletoe compound enters clinical trials.
A drug has entered clinical trials that contains a recombinant version of the main extract from mistletoe, adn holds promise for cancer patients.
Habeck
Martina
M
D000276:Adjuvants, Immunologic / Q000302:isolation & purification / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005060:Europe; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D028321:Plant Preparations / Q000302:isolation & purification / Q000627:therapeutic use*; D010940:Plant Proteins; D054790:Ribosome Inactivating Proteins, Type 2; D014118:Toxins, Biological / Q000302:isolation & purification / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D028321:Plant Preparations; D010940:Plant Proteins; D054790:Ribosome Inactivating Proteins, Type 2; D014118:Toxins, Biological; C009674:ribosome inactivating protein, Viscum